Exer

Name: Exer
Brand: Exer

Clinical AI that improves the quality & efficiency of diagnosis & treatment for MSK and motion disorders.

Est 2019|Valuation $30M|Raised $14.1M|5 Ref Customers

LinkedIn 2K|Web traffic 2K|FTEs 27|HQ Denver, Colorado, US

Published Oct 1, 2026

01Common complaints

1. Organizations with Android-first patient populations or where device standardization on Apple devices is not feasible: iOS-only client availability can materially limit adoption. 2. Organizations that rely heavily on third-party review volume from platforms such as G2 or Capterra to validate vendors: Exer’s presence on major B2B review platforms is limited in this research pass, which increases the diligence burden. 3. Procurements that mandate published third-party security certifications (SOC 2 Type II, ISO 27001) as a precondition: Exer did not have these certifications publicly documented in this research pass. 4. Employers or plans seeking a turnkey, large-scale MSK benefit with broad engagement operations and clinician networks: buyer-aligned alternatives may be more directly suited to that use case.

Deal disqualifiers (poor fit)

Patient populations that primarily use Android devices (given the current iOS-only patient app)
Procurement processes that require publicly documented SOC 2/ISO certifications and cannot accept vendor-supplied documentation under NDA
Buyers seeking a turnkey employer MSK benefit with large-scale engagement operations and clinician networks

Vendor-acknowledged limitations

iOS-only patient app (explicitly stated in support materials). (https://www.exer.ai/support)

Likely technical limitations (not formally disclosed)

Measurement accuracy is likely to vary with camera angle, lighting, clothing, occlusion, and device model.
The vendor’s approach of not storing video may limit retrospective clinician review compared with video-based tele-rehab tools that retain recordings (trade-off between privacy assertions and retrospective review capability).

Roadmap

No public product roadmap or timeline commitments were found in this research pass.

02Why they buy

Vendor-asserted unique selling points (as presented in public materials)

- Vendor claims that the solution does not store patient video in the cloud and performs on-device processing, which the vendor frames as a privacy-oriented approach. (https://www.exer.ai/product/health, https://www.exer.ai/support) - Camera-based (sensor-free) motion analysis using commodity devices is the primary technical differentiator highlighted by the vendor. (https://www.exer.ai/tech) - The vendor reports clinical validation activities and conference presentations that indicate measurement evaluation efforts; underlying study artifacts should be requested for verification. (https://www.exer.ai/posts/exer-ai-clinical-validation-studies-presented-at-assh-and-cns-in-oct-2025)

Areas where competitors may have stronger positioning

Published scale and outcomes data in employer/plan markets and established engagement operations
Outcome-based pricing and commercial models targeted at large purchasers

03Field reports

What public review coverage exists (limitations)

Public review platform coverage for Exer appears limited in this research pass. Searches on major B2B review platforms did not surface a clear Exer product profile with substantive reviews; searches returned similarly named but unrelated products in some cases.

Available review-like sources in this pass include:

App Store ratings for the patient app (limited sample size)
Vendor-published testimonials and case studies
Press coverage

Vendor-published testimonials (examples)

Exer publishes clinician and operator endorsements on its site. Examples include:

A clinician describing accuracy versus manual goniometry.
An academic-affiliated quote on broader impact.
A senior living operator testimonial reporting engagement and soreness outcomes.

Critical note: These are curated vendor-published testimonials and are not independent reviews.

Public app-store signal (limited independent data)

The patient app is moderately rated on the Apple App Store. This is a small sample and cannot be generalized to enterprise deployments.

Common criticisms / friction points (inferred)

Because large-scale independent review content was not found, criticisms are inferred from product constraints, support documentation, and typical implementation issues:

iOS-only patient app: Exer Health currently supports only Apple devices, which may limit reach for Android-heavy populations.
Camera framing and calibration sensitivity: Home environments that do not meet recommended camera positioning and space requirements can lead to measurement issues.

Why customers might choose Exer (evidence)

Public materials and vendor case studies indicate reasons organizations adopt Exer:

Sensor-free motion capture using commodity devices.
Vendor claims regarding privacy (stating no cloud-stored patient videos).
Operational goals: adherence tracking, remote monitoring, and potential alignment with RTM billing codes.

Why some customers might leave (hypotheses)

Potential reasons for churn, based on product limitations and typical procurement concerns, include:

Platform limitations such as iOS-only availability
Integration constraints if EHR workflows are not sufficiently automated
Measurement outcomes not meeting clinician expectations for certain patient populations
Inconsistent reimbursement or billing ROI across payer mixes

Case study: orthopedic surgery (vendor-published)

The vendor case study describes a post-operative monitoring workflow with weekly ROM exercises and increased adherence. Key reported items: - Engagement and adherence were reported as materially higher than an industry standard figure cited in the case study. - Implementation is described in the case study with a vendor-quoted phrase about it being "really seamless." - The case study reports successful RTM billing activity for the example practice. Critical evaluation: - This is a single, vendor-curated story with no disclosed methodology (sample size, time window, selection criteria). - Benchmark figures in the case study are not accompanied by independent sourcing in the vendor materials. - The case study provides directional evidence of workflow feasibility but is not a substitute for independent outcomes research or broader customer references.

Clinical validation claims (vendor summary of presentations)

The vendor highlights validation study presentations that report inter-rater reliability and agreement with manual goniometry, time efficiency comparisons, and measurement accuracy within vendor-claimed tolerances. Critical evaluation: - These reports are summarized in vendor materials; procurement teams should request the underlying abstracts, posters, or peer-reviewed publications and verify the independence of the researchers, study funding, and conflict-of-interest disclosures. - Reported metrics indicate potential measurement utility but require verification in representative clinical populations and operational settings.

Academic collaboration (press release)

A press release announced a collaboration with an academic medical center on hand/wrist disorder protocols and included a disclosure that the institution has a financial interest in the referenced technology.

Critical evaluation:

Collaboration with a recognized academic institution is a credibility indicator; however, the disclosed financial interest should be considered when interpreting reported outcomes and materials associated with the collaboration.

04Best fit

Organization sizes

Most plausible ICP segments based on product framing and workflows:

Specialty clinics and surgical practices: small-to-midsize practices
Health systems and larger provider groups seeking standardized remote assessments and enterprise deployments

Industries / verticals

Orthopedics and post-operative rehabilitation
Senior care and fall-prevention programs
Neurology for tremor and gait assessment

Roles and personas

Decision makers: orthopedic surgeons, rehab directors, digital health/innovation leaders, revenue cycle leaders (for RTM)
End users: physical therapists, occupational therapists, clinical coordinators, care navigators; patients using the iOS app

Qualification criteria (good fit)

Organizations seeking objective motion measurement without procuring wearables or sensors
Patient populations that can access and use Apple devices for home monitoring
Organizations that can operationalize remote monitoring workflows and patient onboarding

05The pitch

What the product does (objective value proposition)

Exer is a clinical AI and computer-vision software platform for musculoskeletal (MSK) and motion disorders. The platform is designed to enable healthcare providers to perform motion assessments (e.g., range of motion, balance, posture) and to monitor patients remotely and/or in clinic without requiring dedicated sensors or wearables by using commodity cameras on smartphones/tablets and on-device/edge AI processing. The vendor describes the platform as privacy-focused and reports that it generates structured motion metrics and reports that clinicians can use for care decisions and, in some workflows, reimbursement. Key product surfaces visible from public materials: - Exer Health (patient-facing iOS app used when prescribed by a provider; remote monitoring and guided exercises) - Provider Portal / dashboards (provider-facing workflows to add patients, assign programs, review metrics) - Validated Evaluation Modules (Balance, Range of Motion, Posture modules)

Target market and positioning

Exer targets provider organizations (orthopedics, rehab/physical therapy, neurology, senior care, primary care, and larger healthcare systems) that seek objective motion measurement, hybrid care workflows, and potentially billable remote monitoring pathways. Public materials emphasize enterprise healthcare adoption and use product positioning aligned with MSK-focused care platforms rather than direct-to-consumer distribution.

Get a comprehensive analysis of Exer including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Oct 1, 2026

01Common complaints

Organizations with Android-first patient populations or where device standardization on Apple devices is not feasible: iOS-only client availability can materially limit adoption.
Organizations that rely heavily on third-party review volume from platforms such as G2 or Capterra to validate vendors: Exer’s presence on major B2B review platforms is limited in this research pass, which increases the diligence burden.
Procurements that mandate published third-party security certifications (SOC 2 Type II, ISO 27001) as a precondition: Exer did not have these certifications publicly documented in this research pass.
Employers or plans seeking a turnkey, large-scale MSK benefit with broad engagement operations and clinician networks: buyer-aligned alternatives may be more directly suited to that use case.

Deal disqualifiers (poor fit)

Patient populations that primarily use Android devices (given the current iOS-only patient app)
Procurement processes that require publicly documented SOC 2/ISO certifications and cannot accept vendor-supplied documentation under NDA
Buyers seeking a turnkey employer MSK benefit with large-scale engagement operations and clinician networks

Vendor-acknowledged limitations

iOS-only patient app (explicitly stated in support materials). (https://www.exer.ai/support)

Likely technical limitations (not formally disclosed)

Measurement accuracy is likely to vary with camera angle, lighting, clothing, occlusion, and device model.
The vendor’s approach of not storing video may limit retrospective clinician review compared with video-based tele-rehab tools that retain recordings (trade-off between privacy assertions and retrospective review capability).

Roadmap

No public product roadmap or timeline commitments were found in this research pass.

02Why they buy

Vendor-asserted unique selling points (as presented in public materials)

Vendor claims that the solution does not store patient video in the cloud and performs on-device processing, which the vendor frames as a privacy-oriented approach. (https://www.exer.ai/product/health, https://www.exer.ai/support)
Camera-based (sensor-free) motion analysis using commodity devices is the primary technical differentiator highlighted by the vendor. (https://www.exer.ai/tech)
The vendor reports clinical validation activities and conference presentations that indicate measurement evaluation efforts; underlying study artifacts should be requested for verification. (https://www.exer.ai/posts/exer-ai-clinical-validation-studies-presented-at-assh-and-cns-in-oct-2025)

Areas where competitors may have stronger positioning

Published scale and outcomes data in employer/plan markets and established engagement operations
Outcome-based pricing and commercial models targeted at large purchasers

03Field reports

What public review coverage exists (limitations)

Available review-like sources in this pass include:

App Store ratings for the patient app (limited sample size)
Vendor-published testimonials and case studies
Press coverage

Vendor-published testimonials (examples)

Exer publishes clinician and operator endorsements on its site. Examples include:

A clinician describing accuracy versus manual goniometry.
An academic-affiliated quote on broader impact.
A senior living operator testimonial reporting engagement and soreness outcomes.

Critical note: These are curated vendor-published testimonials and are not independent reviews.

Public app-store signal (limited independent data)

The patient app is moderately rated on the Apple App Store. This is a small sample and cannot be generalized to enterprise deployments.

Common criticisms / friction points (inferred)

Because large-scale independent review content was not found, criticisms are inferred from product constraints, support documentation, and typical implementation issues:

iOS-only patient app: Exer Health currently supports only Apple devices, which may limit reach for Android-heavy populations.
Camera framing and calibration sensitivity: Home environments that do not meet recommended camera positioning and space requirements can lead to measurement issues.

Why customers might choose Exer (evidence)

Public materials and vendor case studies indicate reasons organizations adopt Exer:

Sensor-free motion capture using commodity devices.
Vendor claims regarding privacy (stating no cloud-stored patient videos).
Operational goals: adherence tracking, remote monitoring, and potential alignment with RTM billing codes.

Why some customers might leave (hypotheses)

Potential reasons for churn, based on product limitations and typical procurement concerns, include:

Platform limitations such as iOS-only availability
Integration constraints if EHR workflows are not sufficiently automated
Measurement outcomes not meeting clinician expectations for certain patient populations
Inconsistent reimbursement or billing ROI across payer mixes

Case study: orthopedic surgery (vendor-published)

The vendor case study describes a post-operative monitoring workflow with weekly ROM exercises and increased adherence. Key reported items:

Engagement and adherence were reported as materially higher than an industry standard figure cited in the case study.
Implementation is described in the case study with a vendor-quoted phrase about it being "really seamless."
The case study reports successful RTM billing activity for the example practice.

Critical evaluation:

This is a single, vendor-curated story with no disclosed methodology (sample size, time window, selection criteria).
Benchmark figures in the case study are not accompanied by independent sourcing in the vendor materials.
The case study provides directional evidence of workflow feasibility but is not a substitute for independent outcomes research or broader customer references.

Clinical validation claims (vendor summary of presentations)

Critical evaluation:

These reports are summarized in vendor materials; procurement teams should request the underlying abstracts, posters, or peer-reviewed publications and verify the independence of the researchers, study funding, and conflict-of-interest disclosures.
Reported metrics indicate potential measurement utility but require verification in representative clinical populations and operational settings.

Academic collaboration (press release)

Critical evaluation:

Collaboration with a recognized academic institution is a credibility indicator; however, the disclosed financial interest should be considered when interpreting reported outcomes and materials associated with the collaboration.

04Best fit

Organization sizes

Most plausible ICP segments based on product framing and workflows:

Specialty clinics and surgical practices: small-to-midsize practices
Health systems and larger provider groups seeking standardized remote assessments and enterprise deployments

Industries / verticals

Orthopedics and post-operative rehabilitation
Senior care and fall-prevention programs
Neurology for tremor and gait assessment

Roles and personas

Decision makers: orthopedic surgeons, rehab directors, digital health/innovation leaders, revenue cycle leaders (for RTM)
End users: physical therapists, occupational therapists, clinical coordinators, care navigators; patients using the iOS app

Qualification criteria (good fit)

Organizations seeking objective motion measurement without procuring wearables or sensors
Patient populations that can access and use Apple devices for home monitoring
Organizations that can operationalize remote monitoring workflows and patient onboarding

05The pitch

What the product does (objective value proposition)

Key product surfaces visible from public materials:

Exer Health (patient-facing iOS app used when prescribed by a provider; remote monitoring and guided exercises)
Provider Portal / dashboards (provider-facing workflows to add patients, assign programs, review metrics)
Validated Evaluation Modules (Balance, Range of Motion, Posture modules)

Target market and positioning

Get a comprehensive analysis of Exer including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →